Adalimumab biosimilar AVT02 equivalent to Originator Humira in Moderate to Severe Chronic Plaque Psoriasis patients with a PASI score at Week 16 of 91.6% for AVT02vs 89.6% for Humira https://t.co/dO4g4aOuON